Stay Up to Date
Breaking News,
Updates, & More
Click Here to
Subscribe

Projected Long-Term Survival High for Patients with Advanced Non–Small-Cell Lung Cancer Treated with Pembrolizumab

TOP - May 2017, Vol 10, No 2 - Lung Cancer
Chase Doyle

Orlando, FL—Durability of benefit (ie, the possibility for sustained remission in patients with previously incurable disease) is already one of the hallmarks of immunotherapy. According to a recent statistical analysis, however, this durability even exceeded expectations.

Based on data from multiple KEYNOTE clinical trials, Matthew D. Hellmann, MD, Medical Oncologist, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, estimates that ≤25% of patients with advanced non–small-cell lung cancer who received pembrolizu­mab will achieve long-term survival. When compared with a long-term survival rate of just 3% to 4% for patients who received chemotherapy, these findings underscore the “remarkable step forward” made with immunotherapy, Dr Hellmann noted.

“We’re cautious to use these sorts of words, but these outcomes really do start to approach the concept of cure for patients with advanced cancer. These aren’t just numbers on a curve or dots on a plot; these are patients that we see in the clinic who are continuing to do well years after being given pembrolizumab,” he said.

As Dr Hellmann reported at the 2017 Society for Immunotherapy of Cancer Clinical Immuno-Oncology Symposium, whereas cytotoxic chemotherapy or tyrosine inhibitors provide some meaningful anticancer responses, progression invariably occurs. With the advent of immunotherapies, however, the survival curve for patients with several types of advanced cancers has fundamentally changed.

“Using conventional modeling, in which we assume that everyone progresses, the proportion of patients with long-term survival is potentially zero. In the context of immunotherapy, however, progression and death is not necessarily inevitable, and long-term survival models must consider the possibility of a plateaued survival when estimating outcomes further out,” said Dr Hellmann.

Using medium-term survival data from KEYNOTE-001 and KEYNOTE-010 studies, in which previously treated patients with PD-L1–positive non–small-cell lung cancer were given pembrolizumab, the investigators projected the percentage of patients who would achieve long-term survival.

“Our approach was to take an initial estimate of long-term survival in patients treated in KEYNOTE-001 and then independently examine data from KEYNOTE-010 to validate the reproducibility of that estimate,” Dr Hellmann explained.

With this model, based on KEYNOTE-001 data, it was estimated that approximately 25.4% of patients receiving pembrolizumab therapy would survive long-term. Further analysis of KEYNOTE-010 cutoff data, which included 6 additional months of patient follow-up, showed a long-term survival estimate of approximately 21.5%. By contrast, docetaxel chemotherapy has an estimated long-term survival rate of 3% to 4% in the same patient population.

“The lives and the expectations of these patients has remarkably changed,” said Dr Hellmann, who emphasized that this is just the beginning of research into immunotherapy’s survival benefit.

“We’ve got a lot of work to do in understanding with precision who these people are in the tail of the curve so that we can get them the right therapy from the start,” he concluded.

Related Items
Rearrangement During Transfection (RET) Fusions and Their Role as Oncogenic Drivers
Web Exclusives published on September 16, 2020 in Lung Cancer
Molecular Profiling Is Critical for Optimizing NSCLC Therapy
Web Exclusives published on September 16, 2020 in Lung Cancer
Response to Immune Checkpoint Inhibitors Among Patients with NSCLC with RET Rearrangements
Web Exclusives published on September 16, 2020 in Lung Cancer
Clinical Trials of Targeted Therapies in RET-Rearranged NSCLC
Web Exclusives published on September 16, 2020 in Lung Cancer
Unmet Needs in NSCLC
Web Exclusives published on September 16, 2020 in Lung Cancer
Durvalumab plus Chemotherapy Improves Overall Survival in Extensive-Stage Small-Cell Lung Cancer
Patricia Stewart
TOP - September 2020 Vol 13, No 5 published on September 14, 2020 in Lung Cancer
Adjuvant Treatment with Osimertinib Is Highly Effective in EGFR-Mutated Earlier-Stage NSCLC
William King
TOP - September 2020 Vol 13, No 5 published on September 14, 2020 in Lung Cancer
Capmatinib Shows Promise in MET-Amplified Non–Small-Cell Lung Cancer
William King
TOP - September 2020 Vol 13, No 5 published on September 14, 2020 in Lung Cancer
Zepzelca New Therapy Approved for Metastatic Small-Cell Lung Cancer
Web Exclusives published on June 22, 2020 in FDA Updates, Lung Cancer
FDA Approves Cyramza plus Tarceva for First-Line Treatment of Metastatic NSCLC with EGFR Mutation
Web Exclusives published on June 8, 2020 in FDA Updates, Lung Cancer
Last modified: April 27, 2020